- Home
- TFX vs ACAD Comparison
TFX vs ACAD Comparison
Compare TFX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFX
- ACAD
- Stock Information
- Founded
- TFX 1943
- ACAD 1993
- Country
- TFX United States
- ACAD United States
- Employees
- TFX N/A
- ACAD N/A
- Industry
- TFX Medical/Dental Instruments
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- TFX Health Care
- ACAD Health Care
- Exchange
- TFX Nasdaq
- ACAD Nasdaq
- Market Cap
- TFX 5.1B
- ACAD 4.3B
- IPO Year
- TFX N/A
- ACAD 2004
- Fundamental
- Price
- TFX $130.32
- ACAD $23.61
- Analyst Decision
- TFX Hold
- ACAD Buy
- Analyst Count
- TFX 9
- ACAD 21
- Target Price
- TFX $141.57
- ACAD $29.30
- AVG Volume (30 Days)
- TFX 566.9K
- ACAD 1.9M
- Earning Date
- TFX 10-30-2025
- ACAD 11-05-2025
- Dividend Yield
- TFX 1.04%
- ACAD N/A
- EPS Growth
- TFX N/A
- ACAD 615.00
- EPS
- TFX 4.18
- ACAD 1.33
- Revenue
- TFX $3,041,342,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- TFX $10.16
- ACAD $14.01
- Revenue Next Year
- TFX $10.10
- ACAD $11.72
- P/E Ratio
- TFX $31.37
- ACAD $17.82
- Revenue Growth
- TFX 1.11
- ACAD 14.41
- 52 Week Low
- TFX $108.90
- ACAD $13.40
- 52 Week High
- TFX $249.91
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- TFX 60.05
- ACAD 39.78
- Support Level
- TFX $128.32
- ACAD $23.70
- Resistance Level
- TFX $133.18
- ACAD $25.90
- Average True Range (ATR)
- TFX 2.62
- ACAD 0.74
- MACD
- TFX 0.12
- ACAD -0.33
- Stochastic Oscillator
- TFX 69.51
- ACAD 8.16
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.